These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 18196225

  • 1. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
    Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR, Schmouder RL.
    Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
    [Abstract] [Full Text] [Related]

  • 2. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
    Kovarik JM, Riviere GJ, Neddermann D, Maton S, Hunt TL, Schmouder RL.
    J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
    [Abstract] [Full Text] [Related]

  • 3. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
    Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL.
    Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM, Dole K, Riviere GJ, Pommier F, Maton S, Jin Y, Lasseter KC, Schmouder RL.
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [Abstract] [Full Text] [Related]

  • 6. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.
    Kovarik JM, Slade A, Riviere GJ, Neddermann D, Maton S, Hunt TL, Schmouder RL.
    Br J Clin Pharmacol; 2008 Aug; 66(2):199-206. PubMed ID: 18507656
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
    Czendlik CH, Sioufi A, Preiswerk G, Howald H.
    Eur J Clin Pharmacol; 1997 Aug; 52(6):451-9. PubMed ID: 9342580
    [Abstract] [Full Text] [Related]

  • 8. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
    Kovarik JM, Schmouder RL, Barilla D, Büche M, Rouilly M, Berthier S, Wang Y, Van Saders C, Mayer T, Gottlieb AB.
    Ann Pharmacother; 2004 Aug; 38(7-8):1153-8. PubMed ID: 15138297
    [Abstract] [Full Text] [Related]

  • 9. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
    Schmouder R, Serra D, Wang Y, Kovarik JM, DiMarco J, Hunt TL, Bastien MC.
    J Clin Pharmacol; 2006 Aug; 46(8):895-904. PubMed ID: 16855074
    [Abstract] [Full Text] [Related]

  • 10. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.
    Schmouder R, Hariry S, David OJ.
    Eur J Clin Pharmacol; 2012 Apr; 68(4):355-62. PubMed ID: 22071882
    [Abstract] [Full Text] [Related]

  • 11. Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
    Harada T, Wilbraham D, de La Borderie G, Inoue S, Bush J, Camm AJ.
    Br J Clin Pharmacol; 2017 May; 83(5):1011-1027. PubMed ID: 27921320
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics of fingolimod.
    David OJ, Kovarik JM, Schmouder RL.
    Clin Pharmacokinet; 2012 Jan 01; 51(1):15-28. PubMed ID: 22149256
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J, den Daas I, Schmouder R.
    Int J Clin Pharmacol Ther; 2012 Aug 01; 50(8):540-4. PubMed ID: 22735460
    [Abstract] [Full Text] [Related]

  • 14. Ethnic sensitivity study of fingolimod in white and Asian subjects.
    Kovarik JM, Slade A, Voss B, Schmidli H, Riviere GJ, Picard F, Sugita Y, Kawai R, Mee-Lee D, Schmouder RL.
    Int J Clin Pharmacol Ther; 2007 Feb 01; 45(2):98-109. PubMed ID: 17323789
    [Abstract] [Full Text] [Related]

  • 15. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, Hartmann S.
    Drug Metab Dispos; 2011 Feb 01; 39(2):199-207. PubMed ID: 21045200
    [Abstract] [Full Text] [Related]

  • 16. Cardiopulmonary response during exercise of a beta 1-selective beta-blocker (atenolol) and a calcium-channel blocker (diltiazem) in untrained subjects with hypertension.
    Cohen-Solal A, Baleynaud S, Laperche T, Sebag C, Gourgon R.
    J Cardiovasc Pharmacol; 1993 Jul 01; 22(1):33-8. PubMed ID: 7690093
    [Abstract] [Full Text] [Related]

  • 17. Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers.
    Ocwieja M, Meiser K, David OJ, Valencia J, Wagner F, Schreiber SJ, Pleyer U, Ziemer S, Schmouder R.
    Br J Clin Pharmacol; 2014 Dec 01; 78(6):1354-65. PubMed ID: 24976291
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of fingolimod phosphate in healthy participants.
    Wu K, Mercier F, David OJ, Schmouder RL, Looby M.
    J Clin Pharmacol; 2012 Jul 01; 52(7):1054-68. PubMed ID: 22110161
    [Abstract] [Full Text] [Related]

  • 19. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
    Krösser S, Wolna P, Fischer TZ, Boschert U, Stoltz R, Zhou M, Darpo B.
    J Clin Pharmacol; 2015 Sep 01; 55(9):1051-60. PubMed ID: 25855155
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 01; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.